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Very early Alzheimer’s disease (AD) – i.e., AD at stages of mild cognitive impairment (MCI) 
and mild dementia – is characterized by progressive structural and neuropathologic 
changes, such as atrophy or tangle deposition in medial temporal lobes, including hippo-
campus and entorhinal cortex and also adjacent amygdala. While progressively disrupted 
intrinsic connectivity of hippocampus with other brain areas has been demonstrated 
by many studies, amygdala connectivity was rarely investigated in AD, notwithstanding 
its known relevance for emotion processing and mood disturbances, which are both 
important in early AD. Intrinsic functional connectivity (iFC) patterns of hippocampus and 
amygdala overlap in healthy persons. Thus, we hypothesized that increased alteration of 
iFC patterns along AD is not limited to the hippocampus but also concerns the amyg-
dala, independent from atrophy. To address this hypothesis, we applied structural and 
functional resting-state MRI in healthy controls (CON, n = 33) and patients with AD in the 
stages of MCI (AD-MCI, n = 38) and mild dementia (AD-D, n = 36). Outcome measures 
were voxel-based morphometry (VBM) values and region-of-interest-based iFC maps of 
basolateral amygdala, which has extended cortical connectivity. Amygdala VBM values 
were progressively reduced in patients (CON > AD-MCI and AD-D). Amygdala iFC was 
progressively reduced along impairment severity (CON > AD-MCI > AD-D), particularly 
for hippocampus, temporal lobes, and fronto-parietal areas. Notably, decreased iFC was 
independent of amygdala atrophy. Results demonstrate progressively impaired amygdala 
intrinsic connectivity in temporal and fronto-parietal lobes independent from increasing 
amygdala atrophy in very early AD. Data suggest that early AD disrupts intrinsic connec-
tivity of medial temporal lobe key regions, including that of amygdala.
Keywords: alzheimer’s disease, mild cognitive impairment, alzheimer’s dementia, fMri, intrinsic functional 
connectivity, amygdala
TaBle 1 | Demographic and psychometric details from ceraD-naB of 
study groups.
characteristic cOn aD-Mci aD-D F sig.
M (sD) M (sD) M (sD)
Age 56.15 (9.31) 59.61 (9.34) 62.86 (8.90)* 4.60 0.012
Education 10.67 (1.71) 10.52 (1.94) 9.48 (2.82) 2.21 0.117
% male 36.40 55.30 50.00 2.62a 0.207
CERAD total 
score
89.88 (7.84) 67.50 (13.79)* 49.49 (17.49)*§ 74.21 0.000
MMSE 29.44 (0.78) 27.00 (1.93)* 21.91 (5.57)*§ 43.10 0.000
Verbal fluency 23.00 (1.95) 15.53 (6.47)* 11.43 (6.98)*§ 36.27 0.000
Modified BNT 14.72 (0.32) 13.81 (1.56) 11.66 (4.27)*§ 12.28 0.000
Word list learning 23.28 (3.12) 15.81 (4.52)* 10.00 (6.28)*§ 64.68 0.000
Constructional 
praxis
10.56 (0.87) 10.11 (1.54) 8.26 (2.67)* 15.08 0.000
Word list recall 8.78 (1.32) 4.31 (3.53)* 1.94 (2.21)*§ 62.40 0.000
Word list 
recognition
9.94 (0.36) 8.17 (2.16)* 7.85 (2.78)* 10.05 0.000
*Score differs significantly from CON group (p < 0.05).
§Score differs significantly from MCI group (p < 0.05).
aχ2 value calculated with Kruskal–Wallis test.
CON, healthy controls; AD-MCI, mild cognitive impairment due to Alzheimer’s disease; 
AD-D, dementia due to Alzheimer’s disease; CERAD, Consortium to Establish a 
Registry for Alzheimer’s disease; MMSE, Mini–Mental Status Exam; Modified BNT, 
Modified Boston Naming Test.
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inTrODUcTiOn
Alzheimer’s disease (AD) is a neurodegenerative disease, 
which accounts approximately for two-thirds of dementia in 
old age (1). It is well established that neuropathological signs 
of neurodegeneration, such as neurofibrillary tangles and cell 
loss, are detectable in the medial temporal lobes (MTL) at 
early disease stages even before symptom onset, already (2, 
3). Neuropathological changes in the hippocampus appear 
to be associated with impairment of declarative memory (4), 
which often represents one of the first symptoms of AD, already 
present at the stage of mild cognitive impairment (MCI) (5, 6). 
Very early stages as used throughout the manuscript entail early 
symptomatic stages of AD fulfilling the criteria of the National 
Institute on Aging – Alzheimer’s Association for probable AD (7) 
or MCI due to AD (8). In addition, in vivo imaging assessment 
such as resting-state functional MRI (rs-fMRI) demonstrated 
increasingly disrupted intrinsic functional connectivity (iFC, 
i.e., synchronized ongoing activity) of the hippocampus with 
cortical iFC networks, such as the default-mode network (9–11). 
Beyond the hippocampus, careful analysis of post-mortem 
findings demonstrates that, even in early prodromal stages of 
the disease, adjacent parts of the amygdala are affected as well 
(2, 12, 13), and imaging studies consistently found atrophy of 
the amygdala in MCI and AD dementia (AD-D) (14, 15). These 
findings suggest that amygdala connectivity might be disrupted 
by AD, too.
Indeed, one recent study has provided first evidence for 
impaired amygdala iFC in MCI and AD-D (16). The authors of 
this study also reported progression of amygdala iFC impairments 
over time in a small subsample of 13 MCI patients. However, Yao 
and colleagues did not address whether amygdala iFC disruption 
might be influenced by potential amygdala atrophy. iFC is related 
to the structural configuration (17), which should, therefore, be 
considered as a relevant factor of disrupted iFC. Thus, further 
evidence is required to confirm impaired amygdala iFC in dif-
ferent stages of AD and to determine whether alterations remain 
significant after controlling for structural volume decreases.
To address this question, we used structural and rs-fMRI in 
healthy subjects (CON), patients with MCI due to AD (AD-MCI), 
and AD-D. We specified our analysis to the basolateral amyg-
dala subdivision, which is tightly coupled to hippocampus and 
temporal regions and characterized by extended cortical iFC 
pattern, including areas early affected by AD (18). Outcome 
measures were voxel-based morphometry (VBM) values and 
region-of-interest (ROI)-based functional connectivity maps 
of the amygdala, reflecting global brain and amygdala volumes 
and iFC, respectively. Statistical group contrasts of iFC maps 
were corrected for amygdala volume, age, total brain volume, 
and sex. We hypothesized progressively reduced amygdala iFC 
in AD-MCI and AD-D, independently from amygdala atrophy.
MaTerials anD MeThODs
subjects
Thirty-three healthy controls (CON), 38 patients diagnosed 
with AD-MCI, and 36 patients with AD-D participated in 
the study. A summary of subjects’ demographics and relevant 
clinical information is listed in Table 1. All participants were 
recruited from the memory clinic of the Department of 
Psychiatry, Klinikum rechts der Isar, Technische Universität 
München (TUM), Munich, Germany. Subjects provided writ-
ten-informed consent before participating in the study, which 
was approved by the Ethics Commission at the TUM. For all 
participants clinical examinations included interviews, in the 
case of patients also with an informant as well as psychiatric, 
neurological, and physical examinations, structural MRI, and 
routine laboratory blood tests. Psychometric evaluation was 
based on the Neuropsychological Assessment Battery of the 
Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD-NAB) (19). Clinical diagnosis was established by 
consensus in a multidisciplinary team. All patients fulfilled 
National Institute on Aging – Alzheimer’s Association criteria 
for probable AD (7) or MCI due to AD with decreased Aβ42 in 
cerebral spinal fluid (CSF), and/or reduced glucose metabolism 
in the temporoparietal cortex on FDG-PET (8). Exclusion 
criteria were severe white matter (WM) hyperintensities, other 
major neurological conditions, such as other types of dementia 
(e.g., vascular dementia, Lewy bodies), other neurodegenera-
tive diseases (e.g., Huntington’s disease, fronto-temporal lobe 
degeneration), stroke, brain tumors, and other systemic diseases 
that affect brain function. Furthermore, patients had to be 
free of current clinical symptoms of psychiatric disorders as 
assessed by a psychiatrist (anxiety, major depression). Patients 
with previous depressive symptoms who did not meet criteria 
for a major depressive episode under medication were allowed 
in the study. In the respective groups (AD-D/AD-MCI/CON), 
16/16/8 participants were treated for hypertension (beta-
blockers, ACE-inhibitors, calcium channel blockers), 14/10/11 
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for hypercholesterolemia (statins), 3/1/1 individuals were diag-
nosed with diabetes mellitus, and 6/5/0 received antidepressant 
medication (mirtazapine, escitalopram, fluoxetine). Four 
patients diagnosed with AD-MCI and all patients with AD-D 
received cholinesterase inhibitors; except for two that were 
treated with the glutamatergic N-Methyl-d-aspartate receptor 
(NMDAR) antagonist memantine. Controls were free of any 
psychotropic medication, did not show psychometric (CERAD-
NAB) deficits, and CDR score was 0.
All participants underwent 10  min of resting-state fMRI 
and about 5 min of structural MRI. For fMRI, each participant 
was instructed simply to keep her/his eyes closed, not to think 
of anything particular and not to fall asleep. We verified that 
subjects stayed awake by communicating with them via intercom 
immediately after the fMRI scan.
Mri Data acquisition
Structural and functional MRI of the brain was obtained using 
standard procedures as described previously (20). Imaging 
was performed on a 3-T whole body MR scanner (Achieva, 
Philips, Netherlands) using an 8-channel phase-array head 
coil. T1-weighted structural data were obtained using a 
magnetization-prepared rapid acquisition gradient echo 
sequence (TE = 4 ms, TR = 9 ms, TI = 100 ms, flip angle = 5°, 
FoV =  240  mm ×  240  mm, matrix =  240 ×  240, 170 slices, 
voxel size = 1 mm × 1 mm × 1 mm). Whole-brain fMRI data 
were collected by using a gradient EPI sequence (TE = 35 ms, 
TR =  2000  ms, flip angle =  82°, FoV =  220  mm ×  220  mm, 
matrix = 80 × 80, 32 slices, slice thickness = 4 mm, 0 mm inter-
slice gap; 10 min scan duration resulting in 300 volumes).
Data analysis
Voxel-Based Morphometry
In order to determine structural changes associated with MCI 
and AD-D, we performed VBM following a previously described 
protocol (21). The VBM12 toolbox for SPM1 was used for data 
preprocessing and analysis. Structural images were corrected for 
bias-field inhomogeneity and registered using linear (12-parameter 
affine) and non-linear transformations. Tissue classification into 
gray matter (GM), WM, and CSF was performed within the 
same generative model (22). GM images were modulated to 
account for volume changes based on the normalization process. 
We only considered non-linear volume changes so that subse-
quent analyses were not impacted by differences in head size. 
Images were spatially normalized into the stereotactic space 
of the Montreal Neurological Institute (MNI) and smoothed 
with an 8  mm (FWHM) Gaussian kernel (final voxel size: 
1  mm ×  1  mm ×  1  mm). Further analyses were restricted to 
voxels with an a priori GM probability of >0.1 to avoid borderline 
effects between GM and WM. In order to assess whole-brain 
volumetric GM group differences, we applied a voxel-wise SPM8 
ANOVA with maps of segmented GM images derived from a 
VBM analysis. Group differences were assessed via two-sample 
t-tests (p  <  0.05 family-wise error (FWE) corrected, extent 
1 http://dbm.neuro.uni-jena.de/vbm.html
threshold: 20 voxels). Furthermore, focused VBM analysis of 
amygdala was restricted to ROI templates based on probabilistic 
cytoarchitectonic maps of basolateral amygdala as implemented 
in the Anatomy Toolbox for SPM (302 and 324 voxels for left 
and right amygdala, respectively). Subsequent two-sample t-tests 
were Bonferroni-corrected.
Seed-Based iFC Analysis
For each subject, the first three functional scans were discarded 
due to magnetization effects. SPM8 (Wellcome Department 
of Cognitive Neurology, London) was used for motion correc-
tion, spatial normalization into the stereotactic space of the 
Montreal Neurological Institute (MNI), and spatial smooth-
ing (8  mm ×  8  mm ×  8  mm Gaussian kernel, final voxel size: 
3 mm × 3 mm × 3 mm). To account for potential motion-induced 
artifacts, temporal signal-to-noise ratio (tSNR) and point-to-
point head motion were estimated for each subject (23). Excessive 
head motion (cumulative motion translation or rotation >3 mm 
or 3° and mean point-to-point translation or rotation >0.15 mm 
or 0.1°) was applied as exclusion criterion. Point-to-point motion 
was defined as the absolute displacement of each brain volume 
compared to its previous volume. None of the participants 
had to be excluded. ANOVA yielded no significant differences 
between groups in mean point-to-point translation or rotation 
in any direction (p > 0.30) or in tSNR (p > 0.30). Furthermore, 
we assessed framewise displacement to characterize head move-
ment in our subjects (24). No significant group differences were 
detected in mean framewise displacement. For seed-based iFC 
analysis, regions-of-interest (ROIs) were chosen corresponding 
to bilateral basolateral amygdala as implemented in the Anatomy 
Toolbox for SPM, resulting in ROIs of 88 and 103 voxels for left 
and right amygdala, respectively (25). ROI were transformed for 
analysis by use of MarsBaR (Release 0.42,2). After Butterworth 
bandpass-filtering of all voxel time courses for the frequency 
range from 0.009 to 0.08 Hz, we extracted voxel time courses of 
seed ROIs and reduced them to ROI-representative time courses 
by singular value decomposition, respectively. Each time course 
was entered into a first-level fixed-effects general linear model in 
SPM8, and two separate iFC analyses (i.e., left amygdala, right 
amygdala) were performed for each subject. For each model, 
additional regressors for global GM, WM, CSF BOLD-signal, 
and six movement parameters (three translational and three 
rotational directions) were included as covariates-of-no-interest. 
Thus, individual iFC maps were obtained for left and right amyg-
dala separately.
Group level analyses were performed using a flexible facto-
rial model of analysis of variance (ANOVA) within SPM8 that 
included covariates-of-no-interest: sex, age, and total brain 
matter volume. To account for amygdala volume and atrophy, 
individual amygdala VBM values (separately for left and right 
amygdala, respectively) were calculated, and – in a second model – 
included as covariates-of-no-interest. Factors were group (with 
levels CON, AD-MCI, and AD-D) and ROI (with levels left and 
right amygdala). To increase sensitivity, both ANOVA models 
2 http://marsbar.sourceforge.net/
FigUre 1 | Volumetric group differences across healthy controls (cOn), patients with mild cognitive impairment due to alzheimer’s disease 
(aD-Mci), and patients with dementia due to alzheimer’s disease (aD-D). (a) shows the main effect of groups with respect to atrophy in gray matter regions; 
Bar represents T-values; p < 0.05, FWE corrected. Please cf. to Table S1 in Supplementary Material for details of involved clusters. (B) The y-axis denotes VBM 
values of amygdala (mean of bilateral ROI voxels) for groups depicted on x-axis. Asterisks indicate significant differences, Bonferroni-corrected p values: CON–AD-
MCI: p = 0.001; CON–AD-D: p < 0.001; AD-MCI–AD-D: p = 0.422. Abbreviations: CON, healthy controls; AD-MCI, patients with mild cognitive impairment due to 
Alzheimer’s disease; AD-D, patients with dementia due to Alzheimer’s disease.
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were restricted to explicit masks at a lenient statistical threshold 
based on the conjunction of positive and negative group iFC 
maps (one-sample t-tests p < 0.05, uncorrected). The parameter 
of interest for both ANOVA models was the main effect of group, 
and appropriate post hoc t-tests were applied in order to reveal the 
direction of change. Due to clarity of presentation, we only display 
results regardless of hemispheres. Statistical thresholds were set 
to p < 0.05, FWE corrected, height threshold p < 0.005. Reported 
voxel coordinates correspond to standardized MNI space.
resUlTs
atrophy in Basolateral amygdala in Very 
early aD
Group comparisons revealed decreased amygdala gray matter 
volumes in AD-MCI and AD-D relative to CON (Figure  1B). 
Slightly lower amygdala volumes in AD-D than in AD-MCI were 
not significant in the direct contrast. Beyond amygdala, voxel-
wise ANOVA revealed a typical pattern of atrophy in AD, includ-
ing medial and lateral temporal lobes, parieto-occipital regions, 
insula and cerebellum (Figure 1A and Table S1 in Supplementary 
Material).
aberrant amygdala iFc in Very early aD
In healthy controls, positive amygdala iFC covered frontal 
cortical regions, including the anterior cingulate cortex (ACC) 
and insular cortex, as well as medial and lateral temporal 
regions, somatosensory cortex, small regions of parietal, and 
occipital cortex. Negative amygdala iFC covered dorsomedial 
and lateral frontal regions, medial parietal and lateral occipital 
regions, as well as caudate, thalamus, and cerebellum. In patients 
with AD-MCI, the iFC pattern was similar to those of healthy 
controls, despite few regions dropping below significance after 
correction for multiple testing (e.g., posterior cingulate cortex). 
In AD-D, additional regions did not emerge as significant (e.g., 
ACC). However, overall, our results indicate relatively preserved 
amygdala connectivity in patients (Figure  2, Tables S2–S7 in 
Supplementary Material).
Concerning group comparisons, in the following, we report 
detailed results of the ANOVA model including amygdala VBM 
FigUre 2 | intrinsic whole-brain functional connectivity patterns of amygdala across healthy controls (cOn), patients with mild cognitive 
impairment due to alzheimer’s disease (aD-Mci) and patients with dementia due to alzheimer’s disease (aD-D). Images (a–c) show positively 
correlated activity across groups; images (D–F) show negatively correlated activity across groups as labeled. Displayed are clusters larger than 20 voxels, bars 
represent T-values, p < 0.05, FWE corrected. Abbreviations: CON, healthy controls; AD-MCI, patients with mild cognitive impairment due to Alzheimer’s disease; 
AD-D, patients with dementia due to Alzheimer’s disease.
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values as covariate-of-no-interest (Figure 3). In Figure 4, results 
of the model without amygdala volume values are depicted. 
Results of both models are largely similar. In general, positive 
and negative amygdala iFC is progressively disrupted in patients 
i.e., we observe the pattern CON > AD-MCI, CON > AD-D, and 
AD-MCI >  AD-D (Figure  3, Tables S8–S13 in Supplementary 
Material). Reduced positive amygdala iFC in AD-MCI in com-
parison to CON was found in parieto-occipital regions, insula, 
and hippocampus (Figure 3A). In AD-D, in comparison to CON, 
regions in anterior insula, parahippocampal gyrus, hippocampus, 
temporal pole, and medial prefrontal cortex were additionally 
decoupled in patients (Figure  3B). In line with this finding, 
AD-D patients had reduced amygdala iFC mainly in medial 
temporal and insular regions in comparison to AD-MCI patients 
(Figure  3C). Reduced negative amygdala iFC was detected in 
AD-MCI patients relative to CON in lateral parietal cortices, 
dorsolateral and medial prefrontal cortices, as well as thalamus 
(Figure 3D). In AD-D vs. CON, similar clusters were found but 
with larger extent (Figure 3E). Direct comparison between AD-D 
and AD-MCI confirms this finding by revealing reduced negative 
amygdala iFC in medial and lateral parietal and prefrontal cortices 
(Figure 3F). Increased iFC in patients did not remain significant 
after appropriate statistical correction for multiple testing.
DiscUssiOn
The current study investigated basolateral amygdala iFC in very 
early AD at the stage of MCI. With increased clinical severity of 
the disease, i.e., AD-MCI and AD-D, progressive loss of amygdala 
iFC was observed, independently from amygdala volume loss. 
Together with known hippocampus iFC loss, results indicate that 
early AD disrupts intrinsic connectivity of medial temporal lobe 
key regions.
Bilateral amygdala atrophy in  
Very early aD
We found bilateral amygdala atrophy in patients with AD-MCI 
and AD-D, respectively (Figure  1). This finding replicates 
FigUre 3 | group contrasts of amygdala whole-brain functional connectivity, taking volumetric amygdala differences into account by including 
individual VBM scores as covariates into anOVa models. Upper row (a–c) shows positively correlated activity, lower row (D–F) anticorrelated activity. 
Columns code different group contrasts: (a,D) CON over AD-MCI; (B,e) CON over AD; (c,F) AD-MCI over AD-D. Bars represent T-values, p = 0.05, FWE 
corrected, cluster size ≥ 20 voxels. Abbreviations: CON, healthy controls; AD-MCI, patients with mild cognitive impairment due to Alzheimer’s disease; AD-D, 
patients with dementia due to Alzheimer’s disease.
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previous imaging results (14, 15, 26, 27). Furthermore, our 
data are consistent with findings by Markesbery and colleagues 
comprising longitudinal clinicopathological cohort studies 
(12, 13) and indicating neurofibrillary pathology and neuritic 
plaques in amygdala of patients. Moreover, lower beta-amyloid 
(Aβ-42) levels in CSF were associated with amygdala atrophy 
rates, even in cognitively normal subjects (28). Taken together, 
our structural finding of reduced amygdala volumes adds to 
previous literature, indicating early neurodegeneration in very 
early AD.
Progressively Disrupted amygdala iFc 
independent from amygdala atrophy
In healthy controls, observed positive and negative iFC of amyg-
dala with a number of regions (Figure 2), including the anterior 
cingulate cortex (ACC), insula, and temporal and parietal regions 
for positive iFC and medial and lateral parietal and prefrontal 
cortices for negative iFC, matches previously reported amygdala 
connectivity patterns, indicating the reliability of our approach 
(18, 20, 29). Progressively reduced iFC in patient groups, mainly 
in occipital, insular, and medial temporal regions for positive 
iFC (Figure  4), is in line with previous findings (30). Beyond 
prior studies, we demonstrate that also amygdala negative iFC in 
medial and lateral parietal and prefrontal cortices is progressively 
reduced in patients (Figure  4). Furthermore, we suggest that 
disrupted amygdala iFC is independent from amygdala atrophy 
(Figures 3 and 4). However, it needs to be taken into account that 
further studies are required to examine structural integrity of 
amygdala-cortical tracts and clarify the distinct relation between 
functional connectivity, localized atrophy, and atrophic tracts 
of the amygdala. Moreover, the detailed interaction between 
regions across different groups including switches between 
positive and negative interregional connectivity may further 
increase our understanding of the dynamic interplay, which 
may be assessed by future studies. Taken together, our results 
demonstrate progressive and extended amygdala iFC disruption 
in AD even at the stage of MCI, which affects large parts of the 
cortex and which is of functional nature and is not explained 
sufficiently by amygdala atrophy.
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Methodological issues, clinical, and 
neuropsychological implications
Our finding of disrupted amygdala iFC includes negative iFC 
based on standard seed-based iFC analysis. In particular, our 
analysis procedure included global signal regression to get rid of 
physiological noise (e.g., respiratory- and cardiac-based signals) 
from ongoing fMRI signal at rest. However, several previous stud-
ies demonstrated that global signal regression induces – under 
several conditions – artificial BOLD correlations, particularly 
negative correlations i.e., negative iFC, suggesting careful use of 
global signal regression and negative iFC (31–34). We decided to 
use global signal regression for the following reasons: (i) recent 
studies provided empirical evidence for the biological origin of 
negative BOLD iFC independent from global signal regression 
(31, 35). (ii) Particularly for the AY, negative iFC with fron-
tolimbic areas was reported for awake rats, again independent of 
global signal regression (36). This finding indicates robustness of 
amygdala negative iFC across species, as well as its independence 
from global signal regression. (iii) Previous studies in humans 
used global signal regression when investigating amygdala iFC 
with results largely comparable to those found in animals (29). 
(iv) Recent models of negative iFC suggest that anticorrelations 
emerge as a functional consequence of multiple indirect anatomi-
cal connections and temporal delays (37). As a limitation, we did 
not control for the effect that cardiovascular and antidepressant 
medication might have on BOLD signal and iFC of the amygdale 
(38–40). While current depressive symptoms were an exclusion 
criterion, six patients of the AD-D group and five patients of 
the MCI-AD group were treated with antidepressant drugs. We 
cannot finally rule out, that the observed effects are impacted by 
depressive disorder, even if currently asymptomatic. Furthermore, 
despite taking local amygdala atrophy into account, we cannot 
determine the relation of iFC changes with atrophy of structural 
amygdalo-cortical tracts by the applied measures. Future studies 
e.g., employing diffusion tensor imaging will help to clarify this.
Amygdala and its intrinsic connectivity are involved in 
emotion and mood processing. Impaired emotion and mood 
processing and depressive symptoms are frequently observed in 
FigUre 4 | group contrasts of amygdala whole-brain functional connectivity, without taking volumetric amygdala differences into account. Upper 
row (a–c) shows positively correlated activity, lower row (D–F) anticorrelated activity. Columns code different group contrasts: Figures 3a,D CON over AD-MCI; 
Figures 3B,e CON over AD-D; Figures 3c,F AD-MCI over AD-D. Bars represent T-values, p = 0.05, FWE corrected, cluster size ≥ 20 voxels. Abbreviations: CON, 
healthy controls; AD-MCI, patients with mild cognitive impairment due to Alzheimer’s disease; AD-D, patients with dementia due to Alzheimer’s disease.
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